[go: up one dir, main page]

CU20160003A7 - Pirazololpiridinaminas sustituidas - Google Patents

Pirazololpiridinaminas sustituidas

Info

Publication number
CU20160003A7
CU20160003A7 CUP2016000003A CU20160003A CU20160003A7 CU 20160003 A7 CU20160003 A7 CU 20160003A7 CU P2016000003 A CUP2016000003 A CU P2016000003A CU 20160003 A CU20160003 A CU 20160003A CU 20160003 A7 CU20160003 A7 CU 20160003A7
Authority
CU
Cuba
Prior art keywords
compounds
pirazololpiridinaminas
replaced
preparing
useful
Prior art date
Application number
CUP2016000003A
Other languages
English (en)
Inventor
Dr Ulrich Klar
Dr Lars Wortmann
Dr Georg Kettschau
Dr Keith Graham
Dr Anja Richter
Dr Philip Lienau
Dr Florian Puehler
Dr Kirstin Petersen
Dr Franziska Siegel
Dr Detlev Sülzle
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51162789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160003(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20160003A7 publication Critical patent/CU20160003A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de pirazolpiridinamina sustituidas de fórmula general I ESPACIO PARA LA FÓRMULA según se los describe y define aquí, útiles para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, a métodos para preparar dichos compuestos y a compuestos intermediarios útiles para preparar dichos compuestos.
CUP2016000003A 2013-07-08 2016-01-08 Pirazololpiridinaminas sustituidas CU20160003A7 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13175526 2013-07-08
EP13194902 2013-11-28
EP13195131 2013-11-29
PCT/EP2014/064347 WO2015004024A1 (en) 2013-07-08 2014-07-04 Substituted pyrazolo-pyridinamines

Publications (1)

Publication Number Publication Date
CU20160003A7 true CU20160003A7 (es) 2017-02-02

Family

ID=51162789

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000003A CU20160003A7 (es) 2013-07-08 2016-01-08 Pirazololpiridinaminas sustituidas

Country Status (24)

Country Link
US (1) US20160159789A1 (es)
EP (1) EP3019505A1 (es)
JP (1) JP2016527216A (es)
KR (1) KR20160030239A (es)
CN (1) CN105531279A (es)
AP (1) AP2016009025A0 (es)
AU (1) AU2014289415A1 (es)
CA (1) CA2917380A1 (es)
CL (1) CL2016000038A1 (es)
CR (1) CR20160016A (es)
CU (1) CU20160003A7 (es)
DO (1) DOP2016000007A (es)
EA (1) EA201690183A1 (es)
HK (1) HK1223362A1 (es)
IL (1) IL243273A0 (es)
MX (1) MX2016000163A (es)
NI (1) NI201600006A (es)
PE (1) PE20160125A1 (es)
PH (1) PH12016500054A1 (es)
SG (1) SG11201510391VA (es)
TN (1) TN2016000005A1 (es)
UY (1) UY35651A (es)
WO (1) WO2015004024A1 (es)
ZA (1) ZA201600275B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
WO2016172010A1 (en) * 2015-04-20 2016-10-27 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
RU2019108280A (ru) 2016-08-24 2020-09-25 Аркьюл, Инк. Аминопирролопиримидиноновые соединения и способы их применения
CA3050599A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2021005183A1 (en) 2019-07-10 2021-01-14 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280040T3 (es) * 2003-07-24 2007-09-01 Bayer Pharmaceuticals Corporation Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos.
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2009111279A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
EP2470532A1 (en) * 2009-08-28 2012-07-04 Array Biopharma, Inc. 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
US9351974B2 (en) * 2011-11-10 2016-05-31 OSI Pharmaceuticals, LLC Substituted pteridinones for the treatment of cancer

Also Published As

Publication number Publication date
CA2917380A1 (en) 2015-01-15
NI201600006A (es) 2016-02-12
ZA201600275B (en) 2019-04-24
IL243273A0 (en) 2016-02-29
CL2016000038A1 (es) 2016-07-29
MX2016000163A (es) 2016-04-15
EA201690183A1 (ru) 2016-06-30
EP3019505A1 (en) 2016-05-18
AU2014289415A1 (en) 2016-01-21
PE20160125A1 (es) 2016-03-17
PH12016500054A1 (en) 2016-04-04
JP2016527216A (ja) 2016-09-08
HK1223362A1 (zh) 2017-07-28
SG11201510391VA (en) 2016-01-28
WO2015004024A1 (en) 2015-01-15
AP2016009025A0 (en) 2016-02-29
UY35651A (es) 2015-02-27
US20160159789A1 (en) 2016-06-09
CN105531279A (zh) 2016-04-27
KR20160030239A (ko) 2016-03-16
DOP2016000007A (es) 2016-02-15
CR20160016A (es) 2016-03-04
TN2016000005A1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
MX372669B (es) Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer.
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
EA201692219A1 (ru) Способы получения противовирусных соединений
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CO2017001884A2 (es) Polimorfos de selinexor
GT201500247A (es) Imidazopiridazinas sustituidas
EA201590321A1 (ru) Дейтерированный барицитиниб
UY35333A (es) Compuestos de azabencimidazol
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
LT3552017T (lt) Junginiai, naudotini kaip ripk1 inhibitoriai
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
EA201591449A1 (ru) Способы получения противораковых композиций
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
PH12015502703A1 (en) Pharmaceutical compositions
CL2016000498A1 (es) Proceso para la producción de lactato.
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos